COLLPLANT BIOTECHNOLOGIES LT (CLGN)
IL0004960188 - Common Stock
We assign a fundamental rating of 3 out of 10 to CLGN. CLGN was compared to 565 industry peers in the Biotechnology industry. The financial health of CLGN is average, but there are quite some concerns on its profitability. CLGN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CLGN has reported negative net income.
CLGN had a negative operating cash flow in the past year.
CLGN had negative earnings in 4 of the past 5 years.
CLGN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
CLGN has a Return On Assets of -77.62%. This is in the lower half of the industry: CLGN underperforms 69.04% of its industry peers.
CLGN has a Return On Equity (-102.97%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -77.62% | ||
| ROE | -102.97% | ||
| ROIC | N/A |
ROA(3y)-21.64%
ROA(5y)-44.39%
ROE(3y)-25.56%
ROE(5y)-95.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CLGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLGN has been increased compared to 1 year ago.
CLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CLGN has an Altman-Z score of -4.43. This is a bad value and indicates that CLGN is not financially healthy and even has some risk of bankruptcy.
CLGN has a Altman-Z score of -4.43. This is in the lower half of the industry: CLGN underperforms 60.32% of its industry peers.
CLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.43 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
A Current Ratio of 5.38 indicates that CLGN has no problem at all paying its short term obligations.
CLGN has a Current ratio (5.38) which is in line with its industry peers.
A Quick Ratio of 5.23 indicates that CLGN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.23, CLGN is in line with its industry, outperforming 57.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.38 | ||
| Quick Ratio | 5.23 |
3. Growth
3.1 Past
CLGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -126.67%.
The Revenue for CLGN has decreased by -93.93% in the past year. This is quite bad
The Revenue has been growing by 16.95% on average over the past years. This is quite good.
EPS 1Y (TTM)-126.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-93.93%
Revenue growth 3Y21.3%
Revenue growth 5Y16.95%
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to grow by 24.82% on average over the next years. This is a very strong growth
CLGN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.92% yearly.
EPS Next Y-219.3%
EPS Next 2Y6.03%
EPS Next 3Y24.82%
EPS Next 5YN/A
Revenue Next Year-89.02%
Revenue Next 2Y-6.73%
Revenue Next 3Y9.92%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
CLGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CLGN's earnings are expected to grow with 24.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.03%
EPS Next 3Y24.82%
5. Dividend
5.1 Amount
CLGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
COLLPLANT BIOTECHNOLOGIES LT
NASDAQ:CLGN (12/24/2024, 8:03:49 PM)
3.5
+0.06 (+1.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners21.38%
Inst Owner Change4.21%
Ins Owners31.73%
Ins Owner ChangeN/A
Market Cap40.08M
Analysts82.5
Price Target12.75 (264.29%)
Short Float %0.09%
Short Ratio0.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.53%
Min EPS beat(2)-34.35%
Max EPS beat(2)-30.72%
EPS beat(4)0
Avg EPS beat(4)-76.21%
Min EPS beat(4)-236.13%
Max EPS beat(4)-3.64%
EPS beat(8)1
Avg EPS beat(8)322.67%
EPS beat(12)1
Avg EPS beat(12)168.62%
EPS beat(16)2
Avg EPS beat(16)116.33%
Revenue beat(2)0
Avg Revenue beat(2)-69.49%
Min Revenue beat(2)-100%
Max Revenue beat(2)-38.97%
Revenue beat(4)0
Avg Revenue beat(4)-79.88%
Min Revenue beat(4)-100%
Max Revenue beat(4)-38.97%
Revenue beat(8)3
Avg Revenue beat(8)-28.84%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)25.68%
EPS NQ rev (3m)25.68%
EPS NY rev (1m)-14.74%
EPS NY rev (3m)-14.74%
Revenue NQ rev (1m)-46%
Revenue NQ rev (3m)-46%
Revenue NY rev (1m)-2.85%
Revenue NY rev (3m)-2.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 61.65 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.37 | ||
| P/tB | 2.39 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.36
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0.06
BVpS1.48
TBVpS1.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -77.62% | ||
| ROE | -102.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-21.64%
ROA(5y)-44.39%
ROE(3y)-25.56%
ROE(5y)-95.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 60.46% | ||
| Cap/Sales | 100.46% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.38 | ||
| Quick Ratio | 5.23 | ||
| Altman-Z | -4.43 |
F-Score2
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)138.43%
Cap/Depr(5y)154%
Cap/Sales(3y)152.96%
Cap/Sales(5y)106.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-126.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-219.3%
EPS Next 2Y6.03%
EPS Next 3Y24.82%
EPS Next 5YN/A
Revenue 1Y (TTM)-93.93%
Revenue growth 3Y21.3%
Revenue growth 5Y16.95%
Sales Q2Q%-100%
Revenue Next Year-89.02%
Revenue Next 2Y-6.73%
Revenue Next 3Y9.92%
Revenue Next 5YN/A
EBIT growth 1Y-157.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.6%
OCF growth 3YN/A
OCF growth 5YN/A